In the wake of several European countries suspending the use of the AstraZeneca COVID-19 vaccine, the company has said that there has been no evidence of increased blood clot risk from its jab. The suspensions have come amid several reports of blood clots following vaccinations with the COVID-19 jab developed by the British-Swedish pharmaceutical giant and the University of Oxford.

“Safety is of paramount importance and the company is continually monitoring the safety of its vaccine,” the company said in a statement. “A careful review of all available safety data of more than 17 million people vaccinated in the EU and UK with COVID-19 vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” it added.